Cresco Labs Résultats passés
Passé contrôle des critères 0/6
Cresco Labs a connu une croissance annuelle moyenne de ses bénéfices de 19.3%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 19.2% par an. Les revenus ont augmenté de en baisse à un taux moyen de 2.3% par an.
Informations clés
19.30%
Taux de croissance des bénéfices
26.31%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 23.06% |
| Taux de croissance des recettes | -2.30% |
| Rendement des fonds propres | -58.07% |
| Marge nette | -20.90% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • Jul 02
CL: Expanded Ohio Dispensary Footprint Will Support Future Upside Potential
Analysts have adjusted their CA$ fair value estimate for Cresco Labs from about CA$2.42 to roughly CA$2.72, reflecting updated views on its revenue outlook, profit margins, discount rate and future P/E assumptions. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, the company’s second Ohio dispensary opening in the past month.
Mise à jour du récit • Jun 18
CL: Texas License And Expanded Ohio Stores Will Support Upside Skewed Profile
Analysts have nudged their fair value estimate for Cresco Labs stock from about CA$2.25 to roughly CA$2.35 per share, reflecting updated assumptions around discount rates, revenue growth, and future P/E expectations. What’s in the News for Cresco Labs Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second Ohio dispensary opening in the past month, bringing its footprint to eight locations in the state and 74 nationally.Mise à jour du récit • Jun 04
CL: Expanded Footprint And Texas License Will Support A More Upside Skewed Profile
Analysts trimmed their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions around revenue growth, discount rate, profit margin and future P/E that together support a slightly lower fair value estimate. What's in the News Cresco Labs opened Sunnyside Aberdeen in Aberdeen, Ohio, its second new Ohio dispensary in the past month, bringing the footprint to eight locations in the state and 74 nationally.Mise à jour du récit • May 05
CL: Lower P/E Expectations Will Support A More Upside Skewed Profile
Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.Mise à jour du récit • Apr 20
CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.Mise à jour du récit • Apr 05
CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating
Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.Mise à jour du récit • Mar 22
CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook
Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.Mise à jour du récit • Mar 07
CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook
Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.Mise à jour du récit • Feb 21
CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook
Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).Article d’analyse • Feb 12
Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
Cresco Labs Inc. ( CSE:CL ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...Mise à jour du récit • Feb 06
CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook
Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).Mise à jour du récit • Jan 23
CL: New German Entry Will Support Future Upside
Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.Mise à jour du récit • Jan 09
CL: German Entry And Higher Margins Will Support Future Upside
Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).Mise à jour du récit • Dec 15
CL: Expanded Retail And European Entry Will Support Stronger Profitability
Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).Article d’analyse • Nov 26
Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%
Unfortunately for some shareholders, the Cresco Labs Inc. ( CSE:CL ) share price has dived 37% in the last thirty days...Article d’analyse • Nov 08
Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Oct 12
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking
Despite an already strong run, Cresco Labs Inc. ( CSE:CL ) shares have been powering on, with a gain of 35% in the last...Article d’analyse • Sep 06
Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?
Key Insights Cresco Labs' estimated fair value is CA$3.23 based on 2 Stage Free Cash Flow to Equity Current share price...Article d’analyse • Jul 31
Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking
Cresco Labs Inc. ( CSE:CL ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Article d’analyse • Jul 23
Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Article d’analyse • Jun 15
Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 30...Article d’analyse • May 01
Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up
Cresco Labs Inc. ( CSE:CL ) shareholders would be excited to see that the share price has had a great month, posting a...
Nouveau récit • Mar 29
Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand
Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.Article d’analyse • Mar 07
Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 27...Article d’analyse • Jan 31
Is Cresco Labs (CSE:CL) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Article d’analyse • Dec 14
Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet
To the annoyance of some shareholders, Cresco Labs Inc. ( CSE:CL ) shares are down a considerable 28% in the last...Article d’analyse • Oct 24
Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely
It's not a stretch to say that Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.8x right now seems...Article d’analyse • Aug 11
Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates
Investors in Cresco Labs Inc. ( CSE:CL ) had a good week, as its shares rose 3.4% to close at CA$2.15 following the...Article d’analyse • Jul 17
Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?
Key Insights Cresco Labs' estimated fair value is CA$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...Article d’analyse • Jun 19
Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Jun 19
Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 26...Article d’analyse • Mar 16
Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41
The investors in Cresco Labs Inc. 's ( CSE:CL ) will be rubbing their hands together with glee today, after the share...Article d’analyse • Mar 03
Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%
Cresco Labs Inc. ( CSE:CL ) shareholders won't be pleased to see that the share price has had a very rough month...Article d’analyse • Jan 26
Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Cresco Labs gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 641 | -134 | 227 | 0 |
| 31 Dec 25 | 656 | -135 | 227 | 0 |
| 30 Sep 25 | 673 | -52 | 229 | 0 |
| 30 Jun 25 | 688 | -46 | 234 | 0 |
| 31 Mar 25 | 708 | -84 | 238 | 0 |
| 31 Dec 24 | 724 | -74 | 233 | 0 |
| 30 Sep 24 | 733 | -67 | 227 | 0 |
| 30 Jun 24 | 741 | -172 | 232 | 0 |
| 31 Mar 24 | 747 | -155 | 239 | 0 |
| 31 Dec 23 | 756 | -176 | 257 | 0 |
| 30 Sep 23 | 767 | -339 | 284 | 0 |
| 30 Jun 23 | 786 | -234 | 295 | 0 |
| 31 Mar 23 | 806 | -211 | 307 | 0 |
| 31 Dec 22 | 825 | -212 | 310 | 0 |
| 30 Sep 22 | 842 | -65 | 295 | 0 |
| 30 Jun 22 | 848 | -326 | 295 | 0 |
| 31 Mar 22 | 841 | -318 | 292 | 0 |
| 31 Dec 21 | 806 | -320 | 276 | 0 |
| 30 Sep 21 | 750 | -360 | 276 | 0 |
| 30 Jun 21 | 687 | -73 | 246 | 0 |
| 31 Mar 21 | 573 | -105 | 215 | 0 |
| 31 Dec 20 | 463 | -102 | 199 | 0 |
| 30 Sep 20 | 345 | -76 | 163 | 0 |
| 30 Jun 20 | 231 | -98 | 145 | 0 |
| 31 Mar 20 | 168 | -64 | 119 | 0 |
| 31 Dec 19 | 124 | -43 | 92 | 0 |
| 30 Sep 19 | 101 | -20 | 77 | 0 |
| 30 Jun 19 | 78 | -14 | 63 | 0 |
| 31 Mar 19 | 57 | -12 | 46 | 0 |
| 31 Dec 18 | 41 | -2 | 31 | 0 |
| 30 Sep 18 | 28 | 0 | 19 | 0 |
| 30 Jun 18 | 19 | 1 | 9 | 0 |
| 31 Mar 18 | 13 | 1 | 7 | 0 |
| 31 Dec 17 | 10 | -3 | 5 | 0 |
| 31 Dec 16 | 3 | -8 | 4 | 0 |
Des revenus de qualité: CL n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: CL n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: CL n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 19.3% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de CL au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: CL n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( 96.7% ).
Rendement des fonds propres
ROE élevé: CL a un retour sur capitaux propres négatif ( -58.07% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/06 16:18 |
| Cours de l'action en fin de journée | 2026/07/03 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Cresco Labs Inc. est couverte par 11 analystes. 6 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Frederico Yokota Choucair Gomes | ATB Cormark |
| Luke Hannan | Canaccord Genuity |